TY - JOUR
T1 - Retinoic acid syndrome
T2 - Manifestations, pathogenesis, and treatment
AU - Larson, Richard S.
AU - Tallman, Martin S.
PY - 2003
Y1 - 2003
N2 - All-trans retinoic acid (ATRA) is a potent differentiation agent that is effective therapy in acute promyelocytic leukaemia. Although ATRA is generally well tolerated, some patients develop retinoic acid syndrome. This syndrome is manifested by unexplained fever, weight gain, respiratory distress, interstitial pulmonary infiltrates, pleural and pericardial effusion, episodic hypotension, and acute renal failure. However, if identified early enough, effective therapy can be administered. This chapter discusses the clinical aspects and pathogenesis of retinoic acid syndrome.
AB - All-trans retinoic acid (ATRA) is a potent differentiation agent that is effective therapy in acute promyelocytic leukaemia. Although ATRA is generally well tolerated, some patients develop retinoic acid syndrome. This syndrome is manifested by unexplained fever, weight gain, respiratory distress, interstitial pulmonary infiltrates, pleural and pericardial effusion, episodic hypotension, and acute renal failure. However, if identified early enough, effective therapy can be administered. This chapter discusses the clinical aspects and pathogenesis of retinoic acid syndrome.
KW - Acute promyelocytic leukaemia
KW - Retinoic acid syndrome
UR - http://www.scopus.com/inward/record.url?scp=0042830246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042830246&partnerID=8YFLogxK
U2 - 10.1016/S1521-6926(03)00043-4
DO - 10.1016/S1521-6926(03)00043-4
M3 - Review article
C2 - 12935962
AN - SCOPUS:0042830246
SN - 1521-6926
VL - 16
SP - 453
EP - 461
JO - Best Practice and Research in Clinical Haematology
JF - Best Practice and Research in Clinical Haematology
IS - 3
ER -